Kurzfassung

Randomized, double-blind, placebo-controlled phase 3 study of the Bruton's Tyrosine Kinase (BTK) inhibitor PCI-32765 (Ibrutinib) in combination with Bendamustine and Rituximab (BR) in subjects with newly diagnosed mantle cell lymphoma.